Biopharmaceutical company TFF Pharmaceuticals Inc (NASDAQ:TFFP) disclosed on Monday that it recorded a net loss of USD2.8m for the third quarter 2019.
This reflects a decline in earnings when compared with a net loss of USD585,215 for the comparable period in 2018.
Research and Development (R&D) expenses of USD2.6m were recorded for the third quarter of 2019, fromR&D of USD140,167 for the same period in 2018.
As of 30 September 2019, the company had cash and cash equivalents of USD10.6m.
According to the company, it has begun a Phase 1 clinical trial of its next-generation, direct-to-lung, inhaled dry powder version of Voriconazole for treating Invasive Pulmonary Aspergillosis (IPA). It has also closed its initial public offering of USD24m common stock at a public offering price of USD5.00 per share.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA